A drug originally developed for prostate cancer may have exciting potential for treating Parkinson's, according to research published today in Cell Stem Cell.
Scientists have identified a key molecule - called USP13 - which may provide a new avenue to prevent the build up of alpha-synuclein in brain cells.
Results published today in the scientific journal Science Translational Medicine highlights a link between the removal of the appendix and a reduced risk of developing Parkinson's.
The UK-wide Predict PD study, funded by Parkinson's UK, is seeking 10,000 people aged 60-80 without Parkinson's to find clues to the very earliest stages of the condition.
The pharmaceutical company Biogen has presented promising initial results from trials testing a potential new treatment for Parkinson's which targets the alpha-synuclein protein.
A US study has found that people with Attention-Deficit Hyperactivity Disorder (ADHD) may have an increased risk of developing Parkinson's.
Researchers and drug companies have a new tool in the search for better treatments for Parkinson's - a brain scan that can be used to select the right people for clinical trials.